Ioanna Markaki

Dr. Ioanna Markaki


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
TNTheodora Ntetsika
Theodora Ntetsika
PPParaskevi-Evita Papathoma
Paraskevi-Evita Papathoma
IMIoanna Markaki
Ioanna Markaki
Parkinson’s disease (PD) is the second more common neurodegenerative disease with increasing incidence worldwide associated to the population ageing. Despite increasing awareness and significant research advancements, treatment options comprise dopamine repleting, symptomatic therapies that have significantly increased quality of life and life expectancy, but no therapies that halt or reverse disease progression, which remain a great, unmet goal in PD research. Large biomarker development programs are undertaken to identify disease signatures that will improve patient selection and outcome measures in clinical trials. In this review, we summarize PD-related mechanisms that can serve as targets of therapeutic interventions aiming to slow or modify disease progression, as well as previous and ongoing clinical trials in each field, and discuss future perspectives.

1 January 2014 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
IMIoanna Markaki
Ioanna Markaki
UNUlrik Nilsson
Ulrik Nilsson
KKKonstantinos Kostulas
Konstantinos Kostulas
CSChristina Sjöstrand
Christina Sjöstrand

15 June 2021 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SBSofia Bergström
Sofia Bergström
JRJulia Remnestål
Julia Remnestål
JYJamil Yousef
Jamil Yousef
JOJennie Olofsson
Jennie Olofsson
IMIoanna Markaki
Ioanna Markaki
PNPeter Nilsson
Peter Nilsson
Objective: Decreased amyloid beta (Aβ) 42 together with increased tau and phospho‐tau in cerebrospinal fluid (CSF) is indicative of Alzheimer’s disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.Methods: We utilized an antibody‐based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.Results: Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP‐regulated phosphoprotein 21 (ARPP21), growth‐associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.Interpretation: In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.

26 February 2021 in Movement Disorders
Verified
Journal Article
Open access
PDF file
IMIoanna Markaki
Ioanna Markaki
TNTheodora Ntetsika
Theodora Ntetsika
KSKimmo Sorjonen
Kimmo Sorjonen
Per SvenningssonPer Svenningsson
Per Svenningsson
FGfor the BioPark Study Group
for the BioPark Study Group
Background: The interplay between glycemic control and Parkinson's disease (PD) has long been recognized but not fully understood.Objectives: To investigate the association of glycated hemoglobin (HbA1c) levels with motor and cognitive symptom progression in a prospective PD cohort.Methods: Of 244 PD patients, 17 had low HbA1c (≤30 mmol/mol), 184 were euglycemic (HbA1c 31–41 mmol/mol), 18 had high HbA1c (HbA1 ≥42 mmol/mol), and 25 had diabetes mellitus (DM). Survival analysis was applied on time until Hoehn and Yahr stage ≥3 (motor outcome) and until mild cognitive impairment.Results: Low HbA1c (HR 2.7; 95% CI 1.3–6; P = 0.01) as well as high HbA1c (HR 3.6; 95% CI 1.5–8.9; P = 0.005) but not DM were independent predictors of unfavorable motor outcome.Conclusions: Both high and low HbA1c levels may be associated with motor symptom progression in PD; however, further studies are needed to confirm these findings and increase understanding regarding causality. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

15 August 2020 in Movement Disorders
Verified
Journal Article
Open access
PDF file
IMIoanna Markaki
Ioanna Markaki
SBSofia Bergström
Sofia Bergström
PTPanagiota Tsitsi
Panagiota Tsitsi
JRJulia Remnestål
Julia Remnestål
AMAnna Månberg
Anna Månberg
PSPer Svenningsson
Per Svenningsson
Background: Cognitive impairment is common in patients with PD. Core markers of Alzheimer's dementia have been related also to PD dementia, but no disease‐specific signature to predict PD dementia exists to date.Objectives: The aim of this study was to investigate CSF markers associated with cognition in early PD.Methods: A high‐throughput suspension bead array examined 216 proteins in CSF of 74 PD patients in the AETIONOMY project. Cognitive function was assessed with Repeatable Battery for the Assessment of the Neuropsychological Status, Montreal Cognitive Assessment, and Mini‐Mental State Examination.Results: Of 69 patients with complete data, 34 had high (≥90) and 35 had low Repeatable Battery for the Assessment of the Neuropsychological Status total score (<90). Of 14 proteins in CSF that differed in levels between groups, increased kininogen‐1, validated with several antibodies, was independently associated with lower Repeatable Battery for the Assessment of the Neuropsychological Status and Montreal Cognitive Assessment scores after adjustment for confounders.Conclusions: Kininogen‐1 levels in CSF may serve as a marker of cognitive impairment in PD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

25 July 2022 in Movement Disorders
Verified
Journal Article
Open access
DVDanielle Te Vruchte
Danielle Te Vruchte
ASAndrea Sturchio
Andrea Sturchio
DPDavid Priestman
David Priestman
PTPanagiota Tsitsi
Panagiota Tsitsi
EHEllen Hertz
Ellen Hertz
Per SvenningssonPer Svenningsson
Per Svenningsson
Background: Alteration in glycosphingolipids (GSLs) in Parkinson's disease (PD) still needs to be determined.Objectives: We evaluated if PD subjects show abnormal GSLs levels compared to healthy controls (HC) and if GSLs correlate with clinical features.Methods: We analyzed GSLs and glucosylceramide (GlcCer) in plasma using two normal‐phase high‐performance liquid chromatography assays; clinico‐demographic data were extracted.Results: Eighty PD subjects and 25 HCs were analyzed. Levels of GlcCer, GD1b, Gb4, GalNAcGA1, and b‐series were higher in PD patients than in HCs; total GSLs, GT1b, GM1a, GM3, GM2, and a‐series levels were lower in PD patients than in HCs. Changes in GSLs were present in PD subjects, with GlcCer levels similar to those in HCs. The results were similar after excluding certain GBA1 mutation carriers. Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III, correlated with Gb4 and Montreal Cognitive Assessment with GD1b levels.Conclusions: Multiple GSL abnormalities in plasma were detected in patients with and without GlcCer changes, indicating a broader shift in lipid homeostasis. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.